{"id":"metformin-ir","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"3–5","effect":"Metallic taste"},{"rate":"10–30","effect":"Vitamin B12 deficiency"},{"rate":"<0.1","effect":"Lactic acidosis (rare)"}]},"_chembl":{"chemblId":"CHEMBL1431","moleculeType":"Small molecule","molecularWeight":"129.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that activates AMP-activated protein kinase (AMPK), which suppresses gluconeogenesis in the liver and enhances glucose uptake and utilization in muscle and adipose tissue. It does not stimulate insulin secretion, making it weight-neutral and suitable for use across a range of patient populations. The IR (immediate-release) formulation allows rapid absorption and onset of action.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, lowering blood glucose levels in type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:35.531Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07300033","phase":"PHASE1","title":"Bioequivalence Study of Liquid Metformin (100 and 250 mg/mL) vs IR Tablets","status":"NOT_YET_RECRUITING","sponsor":"Aspargo Labs, Inc","startDate":"2026-05-15","conditions":"Healthy Volunteer","enrollment":24},{"nctId":"NCT07300046","phase":"PHASE1","title":"Tolerability Study of Liquid Metformin (100 and 250 mg/mL) vs IR Tablets","status":"NOT_YET_RECRUITING","sponsor":"Aspargo Labs, Inc","startDate":"2026-06-15","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT06042855","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2023-09-05","conditions":"Covid19","enrollment":3214},{"nctId":"NCT04885530","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":"Covid19","enrollment":10956},{"nctId":"NCT05966792","phase":"NA","title":"SGLT2 Inhibitors in Treating Patients With PCOS","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai 10th People's Hospital","startDate":"2023-11-10","conditions":"Polycystic Ovary Syndrome","enrollment":80},{"nctId":"NCT04288778","phase":"PHASE4","title":"A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes","status":"COMPLETED","sponsor":"Johnson & Johnson Private Limited","startDate":"2020-11-25","conditions":"Diabetes Mellitus","enrollment":276},{"nctId":"NCT05833958","phase":"PHASE2","title":"Polypill Versus Metformin in New Onset Type 2 Diabetes","status":"WITHDRAWN","sponsor":"George Medicines PTY Limited","startDate":"2024-09","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT03507413","phase":"PHASE2, PHASE3","title":"Metformin Therapy in Non-diabetic AAA Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Vienna","startDate":"2018-09-26","conditions":"Abdominal Aortic Aneurysm","enrollment":170},{"nctId":"NCT04854512","phase":"PHASE3","title":"Investigational Study of Delayed Release Metformin","status":"SUSPENDED","sponsor":"Anji Pharma","startDate":"2021-05-18","conditions":"Diabetes Mellitus, Type 2","enrollment":675},{"nctId":"NCT04700839","phase":"PHASE4","title":"SGLT2 Inhibitors in Patients With PCOS","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2020-05-01","conditions":"Polycystic Ovary Syndrome","enrollment":68},{"nctId":"NCT05151146","phase":"PHASE1","title":"A Phase 1 Study of ANJ900 Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Anji Pharma","startDate":"2021-10-15","conditions":"Healthy","enrollment":18},{"nctId":"NCT02491333","phase":"PHASE3","title":"The RCT of Acupuncture on PCOS Combined With IR","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2015-08","conditions":"Polycystic Ovary Syndrome, Insulin Resistance","enrollment":342},{"nctId":"NCT02395237","phase":"PHASE1","title":"COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.","status":"WITHDRAWN","sponsor":"Pharmaceutical Research Unit, Jordan","startDate":"2015-05","conditions":"Healthy","enrollment":""},{"nctId":"NCT04298684","phase":"PHASE4","title":"Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules in Type 2 Diabetes","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de la Guadeloupe","startDate":"2021-01-01","conditions":"Diabetes Mellitus, Type 2, Thyroid Nodule (Benign)","enrollment":90},{"nctId":"NCT04064073","phase":"PHASE1","title":"Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With Metformin in Healthy Male Adults (Phase 1 Study)","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-08-14","conditions":"Healthy","enrollment":34},{"nctId":"NCT01864174","phase":"PHASE4","title":"Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-06-20","conditions":"Type 2 Diabetes Mellitus","enrollment":1736},{"nctId":"NCT02791490","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-06-16","conditions":"Type 2 Diabetes Mellitus","enrollment":458},{"nctId":"NCT02492763","phase":"PHASE2","title":"A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-27","conditions":"Type II Diabetes Mellitus","enrollment":176},{"nctId":"NCT03458208","phase":"PHASE1","title":"Bioequivalence Study of Metformin 1000 mg Tablets Immediate Release (IR) Versus Glucophage® 1000 mg Tablets IR In Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2017-02-14","conditions":"Bioequivalence","enrollment":18},{"nctId":"NCT02526524","phase":"PHASE2","title":"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM","status":"COMPLETED","sponsor":"Elcelyx Therapeutics, Inc.","startDate":"2015-09","conditions":"Type 2 Diabetes Mellitus","enrollment":571},{"nctId":"NCT02722239","phase":"PHASE1","title":"An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-03-30","conditions":"Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT02273050","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12","conditions":"Type 2 Diabetes Mellitus","enrollment":1136},{"nctId":"NCT03061981","phase":"PHASE1","title":"A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2017-03-29","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT01725672","phase":"PHASE1","title":"Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-09-27","conditions":"Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT01204775","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-06","conditions":"Type 2 Diabetes","enrollment":26},{"nctId":"NCT01434186","phase":"PHASE3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT02252965","phase":"PHASE4","title":"Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2014-12","conditions":"Diabetes Mellitus, Type 2","enrollment":532},{"nctId":"NCT02291510","phase":"PHASE1","title":"Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects","status":"COMPLETED","sponsor":"Elcelyx Therapeutics, Inc.","startDate":"2012-10","conditions":"Healthy Subjects","enrollment":20},{"nctId":"NCT01677299","phase":"PHASE1, PHASE2","title":"Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM","status":"COMPLETED","sponsor":"Elcelyx Therapeutics, Inc.","startDate":"2012-05","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT01646320","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT01619059","phase":"PHASE3","title":"Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Type 2 Diabetes","enrollment":315},{"nctId":"NCT02712619","phase":"PHASE1","title":"Pharmacokinetic-Pharmacodynamic Relationship of Metformin in Healthy Volunteers","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-05","conditions":"Healthy","enrollment":20},{"nctId":"NCT02206607","phase":"PHASE1","title":"Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":39},{"nctId":"NCT01065298","phase":"","title":"Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT01535677","phase":"PHASE1","title":"To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-04","conditions":"Type 2 Diabetes Mellitus","enrollment":71},{"nctId":"NCT01525225","phase":"PHASE1","title":"Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes Mellitus","enrollment":4},{"nctId":"NCT00885378","phase":"PHASE3","title":"Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT00899470","phase":"PHASE1","title":"Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00897390","phase":"PHASE1","title":"Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00327015","phase":"PHASE3","title":"A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Diabetes","enrollment":1306},{"nctId":"NCT02221180","phase":"PHASE1","title":"Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-08","conditions":"Bioequivalence","enrollment":2},{"nctId":"NCT02220218","phase":"PHASE1","title":"Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-08","conditions":"Healthy","enrollment":2},{"nctId":"NCT01217892","phase":"PHASE3","title":"Evaluation of Dapagliflozin Taken Twice-daily","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-11","conditions":"Type 2 Diabetes","enrollment":400},{"nctId":"NCT02064374","phase":"PHASE1","title":"Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-02","conditions":"Infection, Human Immunodeficiency Virus","enrollment":30},{"nctId":"NCT01941199","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects","status":"COMPLETED","sponsor":"Dong-A Pharmaceutical Co., Ltd.","startDate":"2013-07","conditions":"Type 2 Diabetes Mellitus","enrollment":36},{"nctId":"NCT01973933","phase":"PHASE1","title":"Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction of Pyrimethamine and Metformin IR","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2013-06","conditions":"Healthy","enrollment":20},{"nctId":"NCT01106677","phase":"PHASE3","title":"The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1284},{"nctId":"NCT01273571","phase":"PHASE1","title":"A Pharmacokinetic and Pharmacodynamic Study of Metformin and Canagliflozin in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-12","conditions":"Healthy","enrollment":18},{"nctId":"NCT01454622","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-09","conditions":"Healthy","enrollment":64},{"nctId":"NCT01459094","phase":"PHASE1","title":"Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-10","conditions":"Healthy","enrollment":24},{"nctId":"NCT01508195","phase":"PHASE1","title":"A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-01","conditions":"Healthy","enrollment":64},{"nctId":"NCT01508182","phase":"PHASE1","title":"A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-01","conditions":"Healthy","enrollment":64},{"nctId":"NCT01463774","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-09","conditions":"Healthy","enrollment":74},{"nctId":"NCT01518712","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-09","conditions":"Healthy","enrollment":64},{"nctId":"NCT01463228","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-09","conditions":"Healthy","enrollment":83},{"nctId":"NCT01525823","phase":"PHASE1","title":"Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-02","conditions":"Healthy Volunteers","enrollment":26},{"nctId":"NCT01055691","phase":"PHASE1","title":"A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Healthy Volunteers","enrollment":120},{"nctId":"NCT00948402","phase":"PHASE3","title":"PED/PEA-15 Protein, PCOS, Obesity, Insulin Sensitivity Indexes, Metformin, Oral Contraceptives","status":"COMPLETED","sponsor":"Federico II University","startDate":"2006-12","conditions":"Polycystic Ovarian Syndrome, Insulin Sensitivity","enrollment":20}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DIARRHOEA"},{"count":1,"reaction":"CONFUSIONAL STATE"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"DRUG DISPENSING ERROR"},{"count":1,"reaction":"DYSPEPSIA"},{"count":1,"reaction":"EROSIVE OESOPHAGITIS"},{"count":1,"reaction":"FALL"},{"count":1,"reaction":"FLATULENCE"},{"count":1,"reaction":"INCORRECT DOSAGE ADMINISTERED"},{"count":1,"reaction":"LETHARGY"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Glucophage","Glucophage® IR","Met IR","Glucophage IR"],"phase":"marketed","status":"active","brandName":"Metformin IR","genericName":"Metformin IR","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, lowering blood glucose levels in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}